A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies
To determine the rate of response and the duration of the response following therapy with Aroplatinin patients with advanced solid malignancies.
Esophageal Neoplasms|Hepatocellular Carcinoma|Colorectal Neoplasms|Ovarian Neoplasms|Pancreatic Neoplasms|Neoplasms
DRUG: Aroplatin (Liposomal NDDP, L-NDDP)
Primary Objective:

* Determine response rate (RR; complete and partial response \[CR, PR\]) and duration after therapy with Aroplatinâ„¢ in patients with advanced solid malignancies.

Secondary Objective:

* Determine the safety and tolerability of Aroplatin